Gilead Sciences, Inc. (FRA:GIS)
Germany · Delayed Price · Currency is EUR | Market Cap | 134.64B |
| Revenue (ttm) | 24.79B |
| Net Income (ttm) | 6.91B |
| Shares Out | n/a |
| EPS (ttm) | 5.47 |
| PE Ratio | 19.48 |
| Forward PE | 15.11 |
| Dividend | 2.82 (2.60%) |
| Ex-Dividend Date | Sep 15, 2025 |
| Volume | 110 |
| Average Volume | 438 |
| Open | 107.62 |
| Previous Close | 108.36 |
| Day's Range | 107.62 - 108.64 |
| 52-Week Range | 82.61 - 111.04 |
| Beta | n/a |
| RSI | 52.85 |
| Earnings Date | Feb 10, 2026 |
About Gilead Sciences
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy p... [Read more]
Financial Performance
In 2024, Gilead Sciences's revenue was $28.75 billion, an increase of 6.04% compared to the previous year's $27.12 billion. Earnings were $480.00 million, a decrease of -91.53%.
Financial numbers in USD Financial StatementsNews
Gilead Sciences: About To Break Out
Gilead Sciences remains a bullish pick, with raised guidance and strong Q3/25 results, driving optimism for continued growth. Gilead Sciences key growth drivers, include robust sales from Livdelzi and...
Gilead Foundation Commits Over $3 Million to Address Food Insecurity
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Foundation today announced that it has committed over $3 million in grants to expand access to food in communities across the United States. Gilead Foundat...
Gilead Sciences: Rating Upgrade Warranted On HIV Division Strength
$100,000 In The S&P 500's 5 Cheapest Healthcare Stocks, 4% Average Dividend Yield
Screening large-cap Health Care names using earnings yield plus ROTC identified five undervalued blue-chip stocks over $100B market cap. Merck, Bristol-Myers, Gilead, Pfizer, and Amgen screen as the c...
$1000 Invested In Gilead Sciences 5 Years Ago Would Be Worth This Much Today
Gilead Sciences (NASDAQ: GILD) has outperformed the market over the past 5 years by 3.03% on an annualized basis producing an average annual return of 16.24%. Currently, Gilead Sciences has a market ...
MRK HIV Regimen Meets Goal in New Study, Gains EU Nod for Keytruda SC
Merck reports strong new HIV study results showing non-inferiority of DOR/ISL to Gilead's Biktarvy and secures an EU approval for its faster-to-administer SC version of Keytruda.
Here is What to Know Beyond Why Gilead Sciences, Inc. (GILD) is a Trending Stock
Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Aspen Neuroscience Announces $115 Million Series C Financing to Accelerate Personalized Cell Therapy Programs
SAN DIEGO , Nov. 20, 2025 /PRNewswire/ -- Aspen Neuroscience, Inc., a clinical-stage biotechnology company pioneering autologous regenerative therapies, today announced the closing of a $115 million S...
Final Trade: TGT, LLY, ORCL, GILD
The final trades of the day with CNBC's Melissa Lee and the 'Fast Money' traders.
Merck's Investigational Two-Drug Regime Matches Gilead's Three-Drug Tablet For HIV Treatment
Merck & Co. Inc. (NYSE: MRK) on Wednesday shared topline results from the Phase 3 trial of an investigational, once-daily, oral, two-drug, single-tablet regimen of doravirine/islatravir (DOR/ISL) in ...
Gilead Sciences, Inc. (GILD) Presents at Jefferies London Healthcare Conference 2025 Transcript
Gilead Sciences (GILD) Announces Executive Leadership Change
Gilead Sciences (GILD) Announces Executive Leadership Change
Merck's (MRK) HIV Treatment Matches Gilead's in Key Trial
Merck's (MRK) HIV Treatment Matches Gilead's in Key Trial
Merck HIV therapy matches Gilead’s Biktarvy in late-stage trial
Insider Sell: Andrew Dickinson Sells Shares of Gilead Sciences Inc (GILD)
Insider Sell: Andrew Dickinson Sells Shares of Gilead Sciences Inc (GILD)
Global drugmakers rush to boost US presence as tariff threat looms
Global drugmakers are rushing to boost U.S. manufacturing and inventory as the Trump administration weighs a 100% tariff on imported branded and patented drugs.
Gilead (GILD) Begins Shipments of HIV Prevention Drug to Africa
Gilead (GILD) Begins Shipments of HIV Prevention Drug to Africa
Gilead Joins Partners for Delivery of First Shipments of Breakthrough Twice-yearly Lenacapavir for HIV Prevention to Sub-Saharan Africa
FOSTER CITY, Calif. & MBABANE, Eswatini--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the delivery of first shipments of lenacapavir – Gilead's twice-yearly injectable HIV-1 c...
Gilead Sciences's Options: A Look at What the Big Money is Thinking
Investors with a lot of money to spend have taken a bullish stance on Gilead Sciences (NASDAQ: GILD). And retail traders should know. We noticed this today when the positions showed up on publicly av...
QYLD, ISRG, GILD, ADBE: ETF Outflow Alert
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Global X Nasdaq 100 Covered Call ETF (Symbol: QYLD) where we have dete...
GILD's Investigational Regimen for HIV Treatment Meets Primary Goal
Gilead's ARTISTRY-1 success boosts shares as its once-daily bictegravir/lenacapavir combo proves non-inferior to complex regimens.
Gilead's One-Pill HIV Treatment Shows Promise In Late-Stage Trial
Gilead Sciences Inc . (NASDAQ: GILD) on Thursday shared topline results from the Phase 3 ARTISTRY-1 trial. The open-label trial evaluated the treatment responses of HIV patients who are virologically...
Gilead's One-Pill HIV Treatment Shows Promise In Late-Stage Trial
Gilead Sciences Inc. (NASDAQ: GILD) on Thursday shared topline results from the Phase 3 ARTISTRY-1 trial.
GILD's Price Target Raised by Needham to $140.00 | GILD Stock News
GILD's Price Target Raised by Needham to $140.00 | GILD Stock News
Gilead Sciences (GILD) Achieves Key Milestone in HIV Treatment Trial
Gilead Sciences (GILD) Achieves Key Milestone in HIV Treatment Trial